Diabetes
Education on Diabetes and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Diabetes and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Diabetes?
Diabetes is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Metabolic conditions affect how the body processes energy and nutrients. The patent includes diabetes among conditions that may relate to AAT status.
What Mark Egly's patent discusses
Due to the link between AATD and diabetes, in one embodiment AAT may be used in preventing, lessening the negative effects of, and treating diabetes in patients, either with or without known AATD. A diagnosis of diabetes may prompt a medical provider to test a patient for AATD or lower AAT levels without being AATD. Alternatively, a patient diagnosed with diabetes may seek genetic testing for AATD through an independent genetic testing company such as 23andMe or geneology.com, a pharmaceutical company supplied test kit or other private methods available. A method for treating a patient suffering from diabetes with AAT begins with the step of determining if the patient is AAT deficient or has lower AAT levels without being AATD. Determining if the patient is AAT deficient or has lower AAT levels without being AATD proceeds as previously described in this disclosure in the section entitled "Determining if a patient is AAT deficient or in the state of having low circulating AAT without being AAT deficient." If the genotyping assay obtained from determining if the patient is AAT deficient indicates that the patient has a SERPINA1 AAT deficient genotype or if the patient's circulating…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Diabetes, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Diabetes, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: